Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 26, 2024 09:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Awarded Target ALS Grant for the Second Time for Development of c-mods for Amyotrophic Lateral Sclerosis (ALS)

Grant to support the in vivo development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS BOSTON, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Dewpoint...
January 16, 2024 09:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model BOSTON, Jan. ...
January 07, 2024 15:00 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS

Patent applications reinforce Dewpoint’s leadership in the discovery of condensate-modifying drugs (c-mods) to treat diseases of high unmet needNew first-in-class composition of matter targeting...
November 07, 2023 01:30 ET | Source: Dewpoint Therapeutics

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...